Clinicopathologic Features, Pathogenesis, and Treatment of Monoclonal Gammopathy-Associated Myopathies
Neurol 105:213101, Soontrapa,P.,et al, 2025
A Brewing Back Pain
NEJM 385:66-72, Pischel, L.,et al, 2021
Neuropathies Associated with Paraproteinemia
NEJM 338:1601-1607, Ropper,A.H.&Gorson,K.C., 1998
CIDP:Clinical Features & Responses to Trtm in 67 Consecutive Pts with/without a Monoclonal Gammopathy
Neurol 48:321-328, Gorson,K.G.,et al, 1997
Plasma Exchange in Polyneuropathy Associated with Monoclonal Gammopathy of Undetermined Significance
NEJM 325:1482-1486, Dyck,P.J.,et al, 1991
A 67-Year-Old Woman with Progressive Tingling Sensations and Imlalance
Neurol 100:151-157, Horta,L.F.B.,et al, 2023
Progressive Camptocormia with Head Drop and Dysphagia
JAMA Neurol 80:209-210, El-Wahsh,S., et al, 2023
Clinicopathologic Conference, Plasm-Cell Myeloma Post-Transplant Lymphoproliferative Disorder
NEJM 386:2508-2516, Case 20-2022, 2022
Clinical Characteristics, Risk Factors, and Outcomes of POEMS Syndrome
Neurol 95:e268-e279, Keddie, S.,et al, 2020
A 64-year-old Man with Progressive Paraspinal Muscle Weakness
Neurol 86:e4-e9, Schneider, R.,et al, 2016
A Young Woman with Blurred Vision and Distal Paresthesias
JAMA Neurol 72:1519-1523, Kung, N.H.,et al, 2015
A 48-year-old Man with Walking Difficulty
Neurol 85:e165-e169, Kalladka, D.,et al, 2015
Stem Cell Transplantation in a Patient With Late-Onset Nemaline Myopathy and Gammopathy
Neurol 71:531-532, Benveniste,O.,et al., 2008
Sporadic Late-Onset Nemaline Myopathy Effectively Treated by Melphalan and Stem Cell Transplant
Neurol 71:532-534,472, Voermans,N.C.,et al., 2008
Neurologic Improvement After Peripheral Blood Stem Cell Transplantation in POEMS Syndrome
Neurol 71:1691-1695, Kuwabara,S.,et al, 2008
Plasma Exchange in Neuroimmunological Disorders: Part 2. Treatment of Neuromuscular Disorders
Arch Neurol 63:1066-1071, Lehmann,H.C.,et al, 2006
The Neurologic Complications of Scleromyxedema
Medicine 80:313-319, Berger,J.R.,et al, 2001
Prognosis of patients with Primary Systemic Amyloidosis Who Present with Dominant Neuropathy
Am J Med 104:232-237, Rajkumar,S.V.,et al, 1998
Fever, Convulsions and Coma in Scleromyxedema:A"Dermato-Neuro Syndrome"
Neurol 46:1778-1779, River,Y.,et al, 1996
A Controlled Study of Intravenous Immunoglobulin in Demyelinating Neuropathy with IgM Gammopathy
Ann Neurol 40:792-795, Dalakas,M.C.,et al, 1996
Intermittent Cyclophosphamide & Prednisone Trtm of Polyneuropathy Assoc with Monocl Gamopathy of Undeter Sign
Neurol 47:1227-1233, Notermans,N.C.,et al, 1996
POEMS Syndrome:A Study of 25 Cases and a Review of the Literature
Am J Med 97:543-553, Soubrier,M.J.,et al, 1994
Multifocal Motor Neuropathy with Conduction Block:Is It a Distinct Clinical Entity?
Neurol 42:497-505, Lange,D.J.,et al, 1992
High-Dose Intravenous Immunoglobulin in the Treatment of Demyelinating Neuropathy with Monoclonal Gammopathy
Neurol 40:212-214, 327-3281990., Cook,D.,et al, 1990
Cyclosporin A in the Treatment of Chronic Demyelinating Polyradiculoneuropathy
JNNP 53:327-330, Hodgkinson,S.J.,et al, 1990
Polyneuropathies Associated with IgM Monoclonal Gammopathies
Arch Neurol 45:1355-1359, Kelly,J.J.,et al, 1988
Treatment of Patients with Neuropathy and Anti-MAG IgM M-Proteins
Ann Neurol 24:93-97, Nobile-Orazio,E.,et al, 1988
Peripheral Neuropathy Associated with Monoclonal IgM Autoantibody
Ann Neurol 22:764-767, Steck,A.J.,et al, 1987
Treatment of Polyneuropathy in Waldenstrom's Macroglobulinemia:Role of Paraproteinemia & Immunologic Studies
Neurol 33:1406-1410, Dalakas,M.C.,et al, 1983
Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease
JAMA Neurol 92:19-29, Salloway,S.,et al, 2025
Inebilizumab for Treatment of IgG4-Related Disease
NEJM 392:1168-1177, Stone,J.H.,et al, 2025
Beyond Glucocorticoids for IgG4-Related Disease
NEJM 392:1232-1233, Spiera,R., 2025
Upadacitinib - An Up-and-Comer for Treatment of Giant-Cell Arteritis
NEJM 392:2062-2064, Koster,M.J. & Warrington,K.J., 2025
A 69-Year-Old Woman with Ophthalmoplegia
Neurol 104:e213763, Yu, H & Frey, J, 2025
A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis
NEJM 392:2309-2320, Nowak,R.J.,et al, 2025
Myasthenia Gravis - Redemption for B-Cell Depletion
NEJM 392:2382-2384, Wolfe,G.I. & Shelly,S., 2025
Efficacy and Safety of Ofatumumab Treatment for Anti-NMDA Receptor Autoimmune Encephalitis (OFF-AE): A Prospective, Multicenter Cohort Study
Ann Neurol 98:80-92, Guo,K.,et al, 2025
Pan-Neurofascin Nodo-Paranodopathy Presenting as Fulminant Guillain-Barre Syndrome
Neurol 105:e213848, Cabral,A.,et al, 2025
New Treatments for Migraine: CGRP Monoclonal Antibodies, Gepants, and Ditans
BMJ 390:e085564, Burch, R. & Rittenberg, E., 2025
Diagnosis and Management of ANCA-Associated Vasculitis
Lancet 403:683-698, Kronbichler, A., et al, 2024
Lecanemab for Alzheimer Disease, Is It Worth It?
Neurol 102:e209265, Nelson,S.E. & Lopez,O.L., 2024
Clinical Presentation, Management, and Outcome in Neurolymphomatosis, A Systematic Review
Neurol 103:e209698, Kaulen.L.D.,et al, 2024
Chronic Immunotherapy for Myasthenia Gravis
www.UptoDate.Com, Bird,S.J., 2024
Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine, A Phase 4, Randomized, Placebo-Controlled Trial
JAMA Neurol 81:1140-1149, Tepper,S.J.,et al, 2024
Lecanemab in Early Alzheimers Disease
NEJM 388:9-21,80, van Dyck,A.H.,et al, 2023
A 60-Year Old Man with Asymmetric Weakness and Persistent Fever
Neurol 100:530-536, Zheng,Y.,et al, 2023
Progressive Hemiparesis and White Matter Abnormalities in an HIV-Negative Patient
Neurol 100:1156-1163, Jabbari,E.,et al, 2023
Donanemab in Early Symptomatic Alzheimer Disease, The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
JAMA 330:512-517, 510, Sims,J.R.,et al, 2023
Polymyalgia Rheumatica
Lancet 402:1459-1472, Espigol-Frigole,G.,et al, 2023